SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June: Dominic Piscitelli, Chief Financial Officer dominic.piscitelli@oricpharma.com info@oricpharma.com Jefferies Global Healthcare Conference – Participating in a fireside chat on Wedn ...

WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1787157 ( ...

Exhibit 99.1 ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025 Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best-in-class profile with strong pharmacokinetic, pharmacodynamic, and safety results in patients with prostate cancer; pro ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ORIC PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) 240 E. Grand Ave, 2nd Floor South San Franci ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-17871 ...

Financial Performance - For the six months ended June 30, 2023, the net loss was $46.9 million, compared to a net loss of $43.4 million for the same period in 2022, reflecting an increase of $3.4 million[65][80]. - The total operating expenses for the six months ended June 30, 2023, were $50.7 million, compared to $44.0 million for the same period in 2022, an increase of $6.7 million[80]. - The company had an accumulated deficit of $381.1 million as of June 30, 2023, primarily due to research and development costs[65]. - Net cash used in operating activities for the six months ended June 30, 2023, was $41.8 million, compared to $40.5 million for the same period in 2022[95]. - The company has not generated any revenue to date and does not expect to until regulatory approval and commercialization of product candidates[89]. Research and Development - Research and development expenses for the three months ended June 30, 2023, were $18.8 million, an increase of $5.0 million from $13.8 million in the same period in 2022[81]. - Total research and development expenses for the three months ended June 30, 2023, were $18.8 million, an increase of $4.9 million compared to $13.8 million in the same period of 2022[83]. - The company expects research and development expenses to increase substantially as it continues to invest in product candidates and clinical trials[83]. - ORIC-114 is currently in a Phase 1b trial for patients with advanced solid tumors, with initial data expected to be reported at the ESMO Congress in October 2023[66]. - ORIC-533 is also in a Phase 1b trial for relapsed/refractory multiple myeloma, with initial data expected in the fourth quarter of 2023[66]. - ORIC-944 is in a Phase 1b trial for advanced prostate cancer, with initial data expected in the first quarter of 2024[66]. Cash and Financing - The company raised gross proceeds of $85.0 million from a private placement of 9,285,710 shares at $7.00 per share on June 24, 2023[66][67]. - Net cash provided by financing activities during the six months ended June 30, 2023, was $85.2 million, primarily from the private placement[98]. - Cash equivalents and investments as of June 30, 2023, totaled $273.7 million, consisting of interest-bearing money market funds, U.S. Treasury securities, and marketable debt instruments[104]. - The net cash used in investing activities for the six months ended June 30, 2023, was $6.5 million, significantly lower than $136.9 million in the same period of 2022[97]. - The company anticipates that its current cash and investments will be sufficient to fund operations into late 2025[90]. Administrative Expenses - General and administrative expenses for the six months ended June 30, 2023, were $12.4 million, a decrease from $13.3 million in the same period in 2022[80]. - General and administrative expenses decreased to $6.2 million for the three months ended June 30, 2023, down from $6.9 million in the same period of 2022, a decrease of $0.7 million[85]. Future Outlook - The company anticipates significant future losses as it continues to develop its product candidates and expand its pipeline[65].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) | | Trading | | | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1787157 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 240 E. Grand Ave, 2 Floor FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REP ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-39269 ORIC PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1787157 (S ...